Bank of America Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. (NYSE:MRK) had its target price lifted by research analysts at Bank of America from $130.00 to $141.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Bank of America‘s price objective points to a potential upside of 9.88% from the stock’s previous close.

MRK has been the topic of several other reports. Wells Fargo & Company dropped their target price on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Royal Bank Of Canada restated an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Citigroup started coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price objective on the stock. Weiss Ratings lowered shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. Finally, Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $131.83.

Merck & Co., Inc. Stock Performance

NYSE MRK traded down $1.06 on Tuesday, reaching $128.32. 4,440,867 shares of the company’s stock traded hands, compared to its average volume of 11,141,493. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $130.29. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The firm has a market cap of $316.92 billion, a price-to-earnings ratio of 36.15, a P/E/G ratio of 2.89 and a beta of 0.21. The stock has a 50 day moving average price of $116.35 and a 200-day moving average price of $114.66.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period last year, the firm earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities research analysts predict that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Chesapeake Wealth Management grew its holdings in shares of Merck & Co., Inc. by 0.6% during the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock worth $1,552,000 after buying an additional 87 shares in the last quarter. South Plains Financial Inc. lifted its stake in shares of Merck & Co., Inc. by 0.6% in the fourth quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock worth $1,635,000 after buying an additional 89 shares in the last quarter. Syverson Strege & Co boosted its position in Merck & Co., Inc. by 2.2% during the fourth quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock worth $436,000 after acquiring an additional 90 shares during the last quarter. Nations Financial Group Inc. IA ADV boosted its position in Merck & Co., Inc. by 0.4% during the first quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company’s stock worth $2,819,000 after acquiring an additional 91 shares during the last quarter. Finally, Westside Investment Management Inc. grew its stake in Merck & Co., Inc. by 3.1% during the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after acquiring an additional 93 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Scotiabank raised its price target on Merck from $136 to $155 and kept a sector outperform rating, signaling continued confidence in upside potential.
• Positive Sentiment: Merck announced a new agreement with the ADAP Crisis Task Force to improve access to HIV treatment, which could support its public health profile and broaden access to IDVYNSO.
• Neutral Sentiment: Several market commentary pieces highlighted Merck’s technical momentum and generally optimistic Wall Street analyst sentiment, which may help reinforce the bullish view but do not appear to be major new catalysts.
• Negative Sentiment: Reuters reported that U.S. lawmakers have opened a national security probe into Merck and other drugmakers over clinical trials in China, raising concerns about due diligence, data protection, and potential links to Chinese military capabilities. Merck, AbbVie probed by US lawmakers over China clinical trials: report

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.